MedTrace Logo

RTX-240 Monotherapy and in Combination With Pembrolizumab

NCT04372706 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2022-12-13

No results posted yet for this study

Summary

Open label, multicenter, multidose, first-in-human Phase 1/2 study of RTX-240 monotherapy or in combination of pembrolizumab for the treatment of patients with (1) relapsed/refractory R/R or locally advanced solid tumors (Phase 1/2) or (2) R/R Acute Myeloid Leukemia (AML) (Phase 1 only).

Conditions

  • Solid Tumor, AML Adult

Interventions

DRUG

RTX-240

Engineered red cells co-expressing 4-1BBL and IL-15TP

DRUG

Pembrolizumab

Humanized immunoglobulin G4 programmed death receptor-1 blocking antibody

Sponsors & Collaborators

  • Rubius Therapeutics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-06
Primary Completion
2022-11-30
Completion
2022-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04372706 on ClinicalTrials.gov